Related Experiment Video
Updated: Aug 7, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Does regular treatment with ketotifen inhibit bronchoconstriction induced by isocapnic hyperventilation?
Ketotifen did not significantly inhibit bronchoconstriction caused by isocapnic hyperventilation in asthma patients. This 12-week study found no difference compared to placebo, suggesting limited efficacy for this specific asthma symptom.
Area of Science:
- Pulmonology
- Clinical Pharmacology
Background:
- Asthma is a chronic respiratory disease characterized by airway inflammation and hyperresponsiveness.
- Isocapnic hyperventilation (IH) is a common method to assess exercise-induced bronchoconstriction in asthma.
Purpose of the Study:
- To evaluate the efficacy of ketotifen in preventing bronchoconstriction induced by isocapnic hyperventilation (IH) in patients with asthma.
- To compare the effects of ketotifen versus placebo on airway hyperresponsiveness to IH.
Main Methods:
- A 12-week, double-blind, placebo-controlled study involving eight asthmatic patients.
- Patients received ketotifen (1 mg twice daily) or placebo.
- Bronchoconstriction was measured following IH challenges after the treatment period.
Main Results:
- No statistically significant difference was observed in the degree of bronchoconstriction induced by IH between the ketotifen and placebo groups.
- Ketotifen did not demonstrate a significant inhibitory effect on IH-induced bronchoconstriction.
Conclusions:
- Ketotifen, at the tested dosage and duration, was not effective in inhibiting bronchoconstriction induced by isocapnic hyperventilation in this cohort of asthma patients.
- Further research may be needed to explore other dosages or patient populations.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...